Tourmaline Bio to Unveil Phase 2 TRANQUILITY Trial Results on Pacibekitug for Chronic Kidney Disease
Tourmaline Bio Inc. will present topline results from its Phase 2 TRANQUILITY trial on May 20, 2025, evaluating the efficacy of pacibekitug in patients with chronic kidney disease and elevated inflammatory markers.
2 minutes to read